GRAViceptive NEGlect Treatment in Acute Stroke Using Targeted Cranial ELECTrotherapy

Graviceptive Neglect After Stroke: Clinical, Neuroanatomical and Physiological Effects of Focal Neuromodulation

GRAViceptive NEGlect Treatment in Acute Stroke Using Targeted Cranial ELECTrotherapy (NCT06747676) is a Phase 1 / Phase 2 interventional studying Stroke, sponsored by University of Sao Paulo. RECRUITING as of the most recent ClinicalTrials.gov update. Talk to your doctor before contacting the trial site.

About This Trial

What Stage of Research Is This?

Phase 1 trials test a new treatment for the first time in humans, focusing on safety, dosing, and how the body processes the drug. For Stroke, a Phase 1 study typically enrolls a small number of participants — often healthy volunteers or patients who have exhausted standard treatment options. Phase 1 results determine whether a treatment moves into larger Phase 2 efficacy studies.

This trial is currently recruiting participants. The sponsor has registered the study with ClinicalTrials.gov as actively enrolling, which means new applicants who meet the eligibility criteria can be considered for screening. Trial status can change between updates — confirm current recruiting status with the study contact before traveling for a screening visit.

With a target enrollment of 28 participants, this is a small study — typical of early-phase research, rare-disease trials, or pilot studies designed to generate preliminary signal before a larger study is launched.

Who May Be Eligible (Plain English)

Who May Qualify: - Supratentorial ischemic stroke diagnosed by neuroimaging and clinical analysis; - Clinically stable (stable vital signs for 24 hours; no chest pain in the last 24 hours; no significant arrhythmia; no evidence of deep vein thrombosis); - Normal or corrected-to-normal vision; - No previous experience with HD-tDCS; - Ability to provide willing to sign a consent form (patient or legal representative); - Ability to comply with the intervention and assessment schedule of the protocol. - Presence of visual verticality misperception. Who Should NOT Join This Trial: - Migraine; - Pregnancy; - Pacemakers; - Seizures; - Claustrophobia; - Transient ischemic attack; - Other neurological disorders; - Psychiatric disorders; - Sensitive scalp or prior brain surgery; - Diagnosis of severe carotid atherosclerotic disease (stenosis ≥ 70%); - Presence of metal implants, cardiac pacemakers, or claustrophobia; - Diagnosis of COVID-19 or other infectious disease that requires isolation; - Uncontrolled medical problems, such as terminal cancer or kidney disease. - Left-handed or mixed-handed individuals as determined using the Edinburgh Handedness Inventory (Appendix 10); - Peripheral vestibular deficits observed using neuro-otological screening tests when the participant's clinical condition allows (head shake test, head thrust test, Dix-Hallpike, and Pagnini-McClure); - Prior musculoskeletal disorders affecting alignment and postural balance (e.g., moderate to severe scoliosis; torticollis); - Cognitive dysfunction outside normal limits on the Mini-Mental State Examination (score below 23); - Global or Wernicke's aphasia; Always talk to your doctor about whether this trial is right for you.

These are translations of the protocol\'s inclusion and exclusion criteria, simplified for patients and caregivers. The original clinical text appears below. Eligibility is ultimately confirmed by the trial site\'s screening process — this summary is a starting point for a conversation with your doctor, not a final determination.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Supratentorial ischemic stroke diagnosed by neuroimaging and clinical analysis; * Clinically stable (stable vital signs for 24 hours; no chest pain in the last 24 hours; no significant arrhythmia; no evidence of deep vein thrombosis); * Normal or corrected-to-normal vision; * No previous experience with HD-tDCS; * Ability to provide informed consent (patient or legal representative); * Ability to comply with the intervention and assessment schedule of the protocol. * Presence of visual verticality misperception. Exclusion Criteria: * Migraine; * Pregnancy; * Pacemakers; * Seizures; * Claustrophobia; * Transient ischemic attack; * Other neurological disorders; * Psychiatric disorders; * Sensitive scalp or prior brain surgery; * Diagnosis of severe carotid atherosclerotic disease (stenosis ≥ 70%); * Presence of metal implants, cardiac pacemakers, or claustrophobia; * Diagnosis of COVID-19 or other infectious disease that requires isolation; * Uncontrolled medical problems, such as terminal cancer or kidney disease. * Left-handed or mixed-handed individuals as determined using the Edinburgh Handedness Inventory (Appendix 10); * Peripheral vestibular deficits observed using neuro-otological screening tests when the participant's clinical condition allows (head shake test, head thrust test, Dix-Hallpike, and Pagnini-McClure); * Prior musculoskeletal disorders affecting alignment and postural balance (e.g., moderate to severe scoliosis; torticollis); * Cognitive dysfunction outside normal limits on the Mini-Mental State Examination (score below 23); * Global or Wernicke's aphasia;

Treatments Being Tested

DEVICE

Active: High-Definition transcranial Direct Current Stimulation (HD-tDCS)

Active high-definition transcranial direct current stimulation (HD-tDCS) will be delivered by a low-intensity direct current stimulator (Soterix Medical) using a 3x1 ring configuration with a central cathode over the contralesional temporo-parietal junction. During the stimulation, participants will perform tasks to stimulate correct visual verticality perception. Six active HD-tDCS sessions of 2mA for 20 minutes HD-tDCS, 3 times daily for 2 days with session intervals greater than 3 hours.

DEVICE

Sham: High-Definition transcranial Direct Current Stimulation (HD-tDCS)

Six sessions (3 times daily for 2 days) of 2mA sham HD-tDCS cathode center over the contralesional TPJ for 20min. Direct current (DC) will be generated by a low-intensity direct current stimulator (Soterix Medical) and then split into the 3 high-density Ag/AgCl sintered ring electrodes. The sham stimulation condition will consist of the same positioning of the electrodes as the active condition, with a ramp-up to 2mA over 30 seconds and a subsequent ramp-down of 30 seconds.

Locations (2)

Trial sites listed on ClinicalTrials.gov for this study. Site activation status can vary — confirm with the specific site before traveling for a screening visit.

Ribeirão Preto Medical School, University of São Paulo

Ribeirão Preto, São Paulo, Brazil

University of São Paulo, Ribeirão Preto Medical School

Ribeirão Preto, São Paulo, Brazil

How to Talk to Your Doctor About This Trial

Bring the printable summary of this trial — including the NCT ID (NCT06747676), the sponsor (University of Sao Paulo), and the key eligibility criteria — to your next appointment. Your doctor can review the inclusion and exclusion criteria against your medical history, lab values, and current treatments to assess whether you are likely to qualify. They can also help you weigh whether trial participation makes sense alongside your existing care plan.

Useful questions to walk through together: What does the trial protocol require beyond standard care? How long is the active treatment phase, and how long is follow-up? Are there study visits at sites I can reach? Who pays for the trial-specific procedures, and who pays for standard-of-care portions? See our 25 questions to ask about clinical trials guide for a more complete checklist.

Authoritative Sources

The official record for this trial lives on ClinicalTrials.gov — the federal registry maintained by the National Library of Medicine at NIH. For background on how this trial fits into the FDA approval pathway, see the FDA drug approval process. For oncology-specific guidance for patients considering trials, the National Cancer Institute publishes patient-oriented overviews. International trial registries are aggregated by the WHO ICTRP.

Frequently Asked Questions

What is the NCT06747676 clinical trial studying?

We aim to determine if targeted high-definition transcranial direct current stimulation (HD-tDCS) can safely correct errors in visual verticality perception in patients after stroke affecting either hemisphere. The full protocol is registered on ClinicalTrials.gov and includes the primary outcome measures, eligibility criteria, and study endpoints.

Who can participate in NCT06747676?

Eligibility for this trial depends on the specific inclusion and exclusion criteria set by the sponsor. The plain-English summary above translates the most important criteria into accessible language; the official clinical text is preserved in the collapsible section underneath. Whether you fit any specific trial is a medical decision your doctor needs to confirm — bring the trial information to your treating physician for a full review against your medical history.

How do I contact the trial site for NCT06747676?

Contact information registered with ClinicalTrials.gov is shown in the sidebar of this page. Before reaching out, confirm with your treating physician that this trial is appropriate for your situation. The trial site will then walk you through the screening process to determine final eligibility.

Is participating in a clinical trial safe?

Clinical trials in the United States are regulated by the FDA and overseen by Institutional Review Boards (IRBs) that review the protocol for safety. Risk varies by trial — Phase 1 studies test new treatments in humans for the first time, while Phase 3 trials use treatments that have already passed earlier safety screening. The informed consent document for any specific trial details the known risks and what to expect. Discuss those risks with your physician before deciding whether to participate.

Where can I verify the data on this page?

Every detail on this page comes directly from the ClinicalTrials.gov API. Click "View on ClinicalTrials.gov" in the sidebar to see the official, unmodified record. The federal record is always authoritative; this page is a structured presentation with a plain-English eligibility translation. For background on how clinical trials are regulated, see the FDA drug approval process documentation.

How This Page Is Built

Every field on this page is pulled directly from the ClinicalTrials.gov API v2 — no estimates, no proxies. The plain-English eligibility translation is generated from the original protocol text and reviewed for fidelity to the underlying clinical criteria. The original clinical text remains visible in the collapsible section above so users and clinicians can verify the translation. Read the full methodology for the data pipeline and known limitations.

Source: ClinicalTrials.gov API v2 record for NCT06747676. Maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. NCT06747676. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · Data from ClinicalTrials.gov.